Replimune Group, Inc. Profile Avatar - Palmy Investing

Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against canc…

Biotechnology
US, Woburn [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Replimune Group, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of REPL's Analysis
CIK: 1737953 CUSIP: 76029N106 ISIN: US76029N1063 LEI: - UEI: -
Secondary Listings
REPL has no secondary listings inside our databases.